Akihiro Yamamoto
Papers
1
Total Citations
4
H-Index
1
About
Dr. Akihiro Yamamoto is a leading urologic oncologist whose research focuses on optimizing multimodal treatment strategies for high-risk prostate cancer, with particular emphasis on neoadjuvant chemohormonal therapy and surgical outcomes. His major contributions center on evaluating the safety and efficacy of combining degarelix acetate with low-dose estramustine phosphate prior to robot-assisted radical prostatectomy, demonstrating that this approach can improve biochemical recurrence-free survival in very high-risk patients. His most cited work (2024, 4 citations) established that dose compliance with this regimen is a critical predictor of treatment success, offering practical guidance for clinical protocols. Dr. Yamamoto’s research bridges the gap between medical oncology and surgical precision, providing evidence-based frameworks for managing aggressive prostate cancer. His findings have direct implications for reducing recurrence rates and refining neoadjuvant protocols, making his work essential reading for urologists and oncologists seeking to improve outcomes in high-risk populations. Through careful analysis of compliance metrics and survival data, Dr. Yamamoto continues to shape the standard of care for patients undergoing multimodal prostate cancer treatment.
Research Focus
Key Achievements
Top Papers
- 1